BioSpace News Archive

Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.

Wall Street is no longer enamored with NASH drug developers.

Genentech, a member of the Roche Group, announced interim results from the Phase III HAVEN 7 study.

Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced a presentation at the American Society of Hematology Annual Meeting in New Orleans.

Vincerx Pharma, Inc. announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022.

Kymera Therapeutics, Inc. presented preclinical data showing that KT-253, a novel MDM2 degrader, inhibited tumor growth as single agent and in combination with venetoclax in AML xenograft models.

Harpoon Therapeutics, Inc. presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma in a poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in person and virtually in New Orleans.

Graphite Bio, Inc. presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel, an investigational gene-edited therapy for sickle cell disease.

MaaT Pharma presented detailed results from the completed Phase 1b CIMON trial with MaaT033 at the Annual Society of Hematology Annual Meeting in New Orleans, U.S.

Poseida Therapeutics, Inc. announced that the Company will present preclinical data from its P-FVIII-101 gene therapy program, partnered with Takeda, at the 2022 American Society of Hematology Annual Meeting being held in New Orleans and virtually December 10–13, 2022.